ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2134

Modifiable Risk Factors and the Development of Psoriatic Arthritis in People with Psoriasis

Amelia Green1,2, Gavin Shaddick3, Rachel Charlton1, Julia Snowball1, Alison L Nightingale1, Catherine Smith4, William Tillet1,5 and Neil McHugh1,5, 1Department of Pharmacy and Pharmacology, The University of Bath, Bath, United Kingdom, 2Department of Mathematical Sciences, The University of Bath, Bath, United Kingdom, 3Centre for Data Science and Statistics, The University of Exeter, Bath, United Kingdom, 4Guy’s and St Thomas’ NHS Foundation Trust, St John’s Institute of Dermatology, London, United Kingdom, 5Royal National Hospital for Rheumatic Diseases, Bath, UK, Bath, United Kingdom

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Electronic Health Record, modifiable risk, primary care, psoriasis and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, October 23, 2018

Title: Epidemiology and Public Health Poster III: SLE, SSc, APS, PsA, and Other Rheumatic Diseases

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriatic Arthritis (PsA) is a progressive and often destructive joint disease that causes pain, swelling and joint stiffness, and can lead to an impaired quality of life. As psoriasis commonly precedes PsA, people with psoriasis provide an important population for studying the effect of modifiable risk factors in the development of PsA.

 

Methods: Incident cases of psoriasis, diagnosed between 1998 and 2014, were identified from the UK Clinical Practice Research Datalink. The association between baseline psoriasis severity, smoking, alcohol consumption and body mass index (BMI) , after adjustment for potential confounders, and development of PsA was assessed using generalised additive models. In addition, the possible non-linear and cumulative/lagged risks associated with change in BMI during follow-up were investigated using distributed lag non-linear models.

 

Results: The base population consisted of 90,189 incident cases of psoriasis (42% males, mean age 51), of which 1409 developed PsA after the record of their psoriasis diagnosis. Significant increases in the risk of developing PsA were observed for BMIs of 25.0-29.9 (ORadj 1.79 (CI95 1.46 – 2.19)), 30.0-34.9 (ORadj 2.10 (CI95 1.67 – 2.63)), and ³35.0 (ORadj 2.68 (CI95 2.09 – 3.43)) compared to <25.0. Increased risks of developing PsA were associated with having severe psoriasis: ORadj 3.40 (CI95 2.83 – 4.08) and alcohol consumption: ORadj 1.13 (CI95 0.7275 – 1.7047), ORadj 1.46 (CI95 1.08 – 1.97) and ORadj 0.77 (CI95 0.46 – 1.29) for ex-, current and heavy drinkers respectively, compared to non-drinkers. Associations with smoking were not significant: ORadj 0.95 (CI95 0.78 – 1.15) and ORadj 0.87 (CI95 0.70 – 1.07) for past and current smokers respectively, compared to non-smokers.

A BMI risk calculator was produced to demonstrate the effects of reductions in BMI on (cumulative) risk of developing PsA (Figure 1). For example, reducing BMI over a 10-year period (linearly) was associated with a reduction in the risk of developing PsA when compared to BMI remaining constant over the same period.

Conclusion: The findings from this study add to the growing evidence that severity of psoriasis, alcohol use and increased BMI are associated with an increased risk of PsA in people psoriasis. Using measurements of BMI over time allowed us to quantify the burden of continuing weight gain on the risk of PsA and, for the first time, we have shown that reducing BMI over time results in a reduction in the risk of PsA. As PsA affects around 20% of people with psoriasis, weight reduction amongst those who are obese may have the potential to greatly reduce their risk of PsA in addition to providing additional health benefits.

Figure 1- Risk calculator for BMI and developing PsA, representing the changes in risk associated with a linear change in BMI  vs constant BMI over a 10 year period. Positive changes (shown in red) indicate an increase in risk with negative changes(in green) indicating reduced risk.


Disclosure: A. Green, None; G. Shaddick, None; R. Charlton, None; J. Snowball, None; A. L. Nightingale, None; C. Smith, None; W. Tillet, None; N. McHugh, None.

To cite this abstract in AMA style:

Green A, Shaddick G, Charlton R, Snowball J, Nightingale AL, Smith C, Tillet W, McHugh N. Modifiable Risk Factors and the Development of Psoriatic Arthritis in People with Psoriasis [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/modifiable-risk-factors-and-the-development-of-psoriatic-arthritis-in-people-with-psoriasis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/modifiable-risk-factors-and-the-development-of-psoriatic-arthritis-in-people-with-psoriasis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology